| 2012年
6月30日 | 2013年
6月30日 | 2014年
6月30日 | 2015年
6月30日 | 2016年
6月30日 | 2017年
6月30日 | 2018年
6月30日 | 2019年
6月30日 | 2020年
6月30日 | 2021年
6月30日 | 2022年
6月30日 | 2023年
6月30日 |
|---|
| Net sales | 315 | 311 | 358 | 452 | 499 | 563 | 643 | 714 | 739 | 931 | 1,106 | 1,137 |
|---|
| Cost of sales | 79 | 79 | 106 | 145 | 162 | 188 | 211 | 241 | 255 | 298 | 349 | 367 |
|---|
| Gross margin | 236 | 231 | 251 | 307 | 337 | 375 | 432 | 473 | 483 | 633 | 756 | 770 |
|---|
| Selling, general and administrative | 42 | 43 | 61 | 119 | 141 | 200 | 241 | 264 | 261 | 325 | 373 | 378 |
|---|
| Research and development | 28 | 29 | 31 | 41 | 45 | 54 | 55 | 62 | 65 | 71 | 87 | 92 |
|---|
| Total operating expenses | 70 | 73 | 92 | 160,254,000 | 186 | 254 | 296 | 327 | 326 | 396 | 460 | 471 |
|---|
| Operating income | 166 | 158 | 160 | 147,022 | 151 | 121 | 136 | 147 | 157 | 237 | 297 | 299 |
|---|
| Interest expense | - | - | - | 2 | 2 | 7 | 10 | 22 | 19 | 14 | 11 | 11 |
|---|
| Interest income | 3 | 3 | 3 | 634,000 | 249,000 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
|---|
| Other non-operating income (expense), net | -3 | -0 | -1 | 8 | -1,613,000 | -2 | -0 | -14 | 138 | -76 | 15 | 48 |
|---|
| Total other income (expense), net | -4 | 2 | 2 | 7 | -3,112,000 | -9 | -10 | -35 | 119 | -89 | 5 | 40 |
|---|
| Earnings before income taxes | 162 | 161 | 161 | 154 | 147 | 112 | 126 | 112 | 276 | 148 | 301 | 339 |
|---|
| Income taxes (benefit) | 50 | 48 | 50 | 46 | 43 | 36 | -0 | 16 | 47 | 9 | 38 | 53 |
|---|
| Net earnings, including noncontrolling interest | - | - | - | - | - | - | - | - | - | 140 | 263 | 285 |
|---|
| Net Income (Loss) Attributable to Noncontrolling Interest | - | - | - | - | - | - | - | - | - | -1 | -9 | 0 |
|---|
| Net earnings attributable to Bio-Techne | 112 | 113 | 111 | 108 | 104 | 76 | 126 | 96 | 229 | 140 | 272 | 285 |
|---|
| Foreign currency translation adjustments | - | - | - | - | - | - | -2 | -4 | -10 | 33 | -32 | 4 |
|---|
| Foreign currency translation reclassified to earnings with Eminence deconsolidation | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent | - | - | - | - | - | - | - | -10 | -4 | 7 | 14 | 5 |
|---|
| Other comprehensive income (loss) | 38 | -7 | -20 | -25 | -40 | 21 | - | - | - | 40 | -18 | 9 |
|---|
| Other comprehensive income (loss) attributable to noncontrolling interest | - | - | - | - | - | - | - | - | - | 0 | -0 | -0 |
|---|
| Other comprehensive income (loss) attributable to Bio-Techne | - | - | - | - | - | - | 4 | -14 | -14 | 40 | -18 | 9 |
|---|
| Comprehensive income attributable to Bio-Techne | 150 | 105 | 91 | 83 | 65 | 98 | 130 | 82 | 216 | 180 | 254 | 294 |
|---|
| Basic (in dollars per share) | 3.04 | 3.06 | 3.01 | 2.9 | 2.81 | 2.04 | 3.36 | 2.54 | 6 | 3.62 | 6.93 | 1.81 |
|---|
| Diluted (in dollars per share) | 3.04 | 3.05 | 3 | 2.89 | 2.8 | 2.03 | 3.31 | 2.47 | 5.82 | 3.47 | 6.63 | 1.76 |
|---|